Related Experiment Video

Updated: Apr 29, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

5.8K

Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects

R Ferraldeschi1, J Welti1, J Luo2

  • 1Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, UK.

Oncogene
|May 20, 2014
PubMed

Insights

Prostate cancer cells adapt to androgen-deprivation therapy (ADT) by maintaining androgen receptor (AR) signaling. This review summarizes castration resistance mechanisms and novel therapeutic strategies targeting AR signaling.

Area of Science:

  • Oncology
  • Molecular Biology
  • Urology

Background:

  • Androgen receptor (AR) signaling is crucial for prostate cancer cell growth.
  • Androgen-deprivation therapy (ADT) is the primary treatment for advanced prostate cancer.
  • Tumor resistance to ADT, leading to castration-resistant prostate cancer (CRPC), is a major clinical challenge.

Purpose of the Study:

  • To review the molecular mechanisms underlying castration resistance in prostate cancer.
  • To provide an update on emerging therapeutic agents and strategies targeting the AR signaling pathway.

Main Methods:

  • Literature review of molecular mechanisms of castration resistance.
  • Analysis of recent advancements in novel therapeutic agents and strategies.
  • Synthesis of current understanding of AR signaling in CRPC.

Main Results:

  • Prostate cancers develop adaptive mechanisms to sustain AR signaling for survival and progression.
  • Understanding these adaptive mechanisms has led to significant treatment advancements.
  • Novel agents and strategies are being developed to overcome resistance.

Conclusions:

  • Castration resistance in prostate cancer involves complex adaptive mechanisms maintaining AR signaling.
  • Targeting AR signaling remains a key strategy for managing CRPC.
  • Continued research into molecular mechanisms will drive the development of more effective treatments.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

46.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K